CYP19A1 and arthritic joint disease: Considering that arthritis and arthralgia are based on a complex inflammatory process, CDK4/6 inhibitors may attenuate E2F2 activity in synovium and cartilage and reverse, at least in part, the inflammation caused by aromatase inhibitors.